Rockefeller Capital Management L.P. Alnylam Pharmaceuticals, Inc. Transaction History

Rockefeller Capital Management L.P.

$36.3 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$146.51 - $198.2 $52,450 - $70,955	-358 Reduced 3.23%	10,715 $1.6 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $319,626 - $414,959	-2,111 Reduced 16.01%	11,073 $2.12 Million
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $2.25 Million - $2.79 Million	13,184 New	13,184 $2.33 Million
Q1 2023 May 17, 2023	SELL	$182.66 - $235.53 $425,963 - $549,255	-2,332 Reduced 21.85%	8,339 $1.67 Million
Q4 2022 Mar 06, 2023	SELL	$185.53 - $241.31 $187,385 - $243,723	-1,010 Reduced 8.65%	10,671 $2.53 Million
Q3 2022 Nov 02, 2022	SELL	$138.54 - $232.0 $840,522 - $1.41 Million	-6,067 Reduced 34.18%	11,681 $2.34 Million
Q2 2022 Aug 12, 2022	SELL	$120.42 - $169.29 $42.9 Million - $60.3 Million	-356,216 Reduced 95.25%	17,748 $2.59 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $1.56 Million - $2.14 Million	-12,296 Reduced 3.18%	373,964 $61.1 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $10.9 Million - $14.3 Million	68,160 Added 21.43%	386,260 $65.5 Million
Q3 2021 Nov 12, 2021	SELL	$169.75 - $207.73 $13.4 Million - $16.5 Million	-79,209 Reduced 19.94%	318,100 $60.1 Million
Q2 2021 Aug 10, 2021	SELL	$128.63 - $176.89 $418,176 - $575,069	-3,251 Reduced 0.81%	397,309 $67.4 Million
Q1 2021 May 11, 2021	BUY	$126.83 - $175.69 $1.5 Million - $2.08 Million	11,815 Added 3.04%	400,560 $56.6 Million
Q4 2020 Feb 12, 2021	BUY	$122.97 - $147.0 $485,608 - $580,503	3,949 Added 1.03%	388,745 $50.5 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $84,711 - $115,677	-699 Reduced 0.18%	384,796 $56 Million
Q2 2020 Aug 12, 2020	BUY	$104.21 - $156.44 $2.44 Million - $3.67 Million	23,440 Added 6.47%	385,495 $57.1 Million
Q1 2020 May 12, 2020	SELL	$93.12 - $133.99 $15 Million - $21.6 Million	-161,094 Reduced 30.79%	362,055 $39.4 Million
Q4 2019 Feb 07, 2020	SELL	$74.51 - $124.23 $4.23 Million - $7.05 Million	-56,727 Reduced 9.78%	523,149 $60.3 Million
Q3 2019 Nov 12, 2019	BUY	$70.9 - $87.82 $6.48 Million - $8.02 Million	91,356 Added 18.7%	579,876 $46.6 Million
Q2 2019 Aug 09, 2019	BUY	$65.86 - $92.79 $56,837 - $80,077	863 Added 0.18%	488,520 $35.4 Million
Q1 2019 May 10, 2019	BUY	$72.76 - $93.45 $80,618 - $103,542	1,108 Added 0.23%	487,657 $45.6 Million
Q4 2018 Feb 12, 2019	BUY	$62.67 - $88.33 $10 Million - $14.1 Million	160,083 Added 49.04%	486,549 $35.5 Million
Q3 2018 Nov 02, 2018	BUY	$87.52 - $122.67 $5.11 Million - $7.16 Million	58,355 Added 21.77%	326,466 $28.6 Million
Q2 2018 Jul 31, 2018	BUY	$88.31 - $107.8 $1.8 Million - $2.19 Million	20,357 Added 8.22%	268,111 $26.4 Million
Q1 2018 May 09, 2018	BUY	$115.92 - $148.54 $28.7 Million - $36.8 Million	247,754 New	247,754 $29.5 Million

Others Institutions Holding ALNY

# of Institutions

650

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.23M

Capital World Investors Los Angeles, CA

16.5M
Shares

$4.48 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$3.43 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.59 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.42 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.34 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.4B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Rockefeller Capital Management L.P. with notifications on news.

Account